-
- Elizabeth C. Nowak
- Department of Microbiology and Immunology Norris Cotton Cancer Center Geisel School of Medicine at Dartmouth Lebanon NH USA
-
- J. Louise Lines
- Department of Microbiology and Immunology Norris Cotton Cancer Center Geisel School of Medicine at Dartmouth Lebanon NH USA
-
- Frederick S. Varn
- Department of Biomedical Data Science and Department of Molecular and Systems Biology Norris Cotton Cancer Center Geisel School of Medicine at Dartmouth Lebanon NH USA
-
- Jie Deng
- Department of Microbiology and Immunology Norris Cotton Cancer Center Geisel School of Medicine at Dartmouth Lebanon NH USA
-
- Aurelien Sarde
- Department of Microbiology and Immunology Norris Cotton Cancer Center Geisel School of Medicine at Dartmouth Lebanon NH USA
-
- Rodwell Mabaera
- Department of Microbiology and Immunology Norris Cotton Cancer Center Geisel School of Medicine at Dartmouth Lebanon NH USA
-
- Anna Kuta
- Department of Microbiology and Immunology Norris Cotton Cancer Center Geisel School of Medicine at Dartmouth Lebanon NH USA
-
- Isabelle Le Mercier
- ImmuNext, Inc. Lebanon NH USA
-
- Chao Cheng
- Department of Biomedical Data Science and Department of Molecular and Systems Biology Norris Cotton Cancer Center Geisel School of Medicine at Dartmouth Lebanon NH USA
-
- Randolph J. Noelle
- Department of Microbiology and Immunology Norris Cotton Cancer Center Geisel School of Medicine at Dartmouth Lebanon NH USA
書誌事項
- 公開日
- 2017-03
- 権利情報
-
- http://onlinelibrary.wiley.com/termsAndConditions#vor
- DOI
-
- 10.1111/imr.12525
- 公開者
- Wiley
この論文をさがす
説明
<jats:title>Summary</jats:title><jats:p>Utilization of negative checkpoint regulators (<jats:styled-content style="fixed-case">NCR</jats:styled-content>s) for cancer immunotherapy has garnered significant interest with the completion of clinical trials demonstrating efficacy. While the results of monotherapy treatments are compelling, there is increasing emphasis on combination treatments in an effort to increase response rates to treatment. One of the most recently discovered <jats:styled-content style="fixed-case">NCR</jats:styled-content>s is <jats:styled-content style="fixed-case">VISTA</jats:styled-content> (V‐domain Ig‐containing Suppressor of T cell Activation). In this review, we describe the functions of this molecule in the context of cancer immunotherapy. We also discuss factors that may influence the use of anti‐<jats:styled-content style="fixed-case">VISTA</jats:styled-content> antibody in combination therapy and how genomic analysis may assist in providing indications for treatment.</jats:p>
収録刊行物
-
- Immunological Reviews
-
Immunological Reviews 276 (1), 66-79, 2017-03
Wiley
